Skip to main content

Intended for Healthcare Professionals

Johnson and Johnson logo graphic link
/en-US

HCP Global Navigation Ribbon

  • Home
  • About Us
      Back
    • About J&J MedTech
    • At-a-Glance
    • Careers
    • Investors
    • Our Companies
  • Our Stories
  • Our Impact
      Back
    • Advancing Health, Improving Lives
    • All Support Resources
    • HCP Education
    • Health System Customer Programs
    • My Health Can’t Wait
    • Sustainability
  • News
  • Contact
  • acclarent logo
  • biosense webster logo
  • cerenovus jjmdc logo
  • DePuy Synthes
  • Ethicon Logo
  • Mentor Logo

Intended for HCPs

Intended for Healthcare Professionals

Secondary nav block

ethicon
  • Home
  • Products
    • All Ethicon Products
    • Adjunctive Hemostats
    • Digital Solutions
    • Energy Sealing & Dissecting
    • LINX Reflux Management
    • Neuwave Microwave Ablation
    • Surgical Stapling
    • Vascular Access & Infection Control
    • Wound Closure
    • Other Products
  • Specialties
    • Bariatric
    • Cardiovascular
    • Colorectal
    • Gynecologic
    • HPB
    • Thoracic
  • Order
  • Support
    • CA Compliance
    • Contributions and Donations
    • Clinical & Technical Support
    • Education Grants
    • Ethicon Product Center (Online Catalog)
    • Instructions for Use
    • Investigator-Initiated Studies
    • Johnson & Johnson Institute
    • Magnetic Resonance Imaging (MRI)
    • Medical Information Request (MIR)
    • Reimbursement
    • Supplemental Terms
  • About Us
    • Careers
    • News
    • Company
  1. Home
  2. Products
  3. GYNECARE TVT™ Sling Retropubic System

GYNECARE TVT™ Sling Retropubic System

GYNECARE TVT™ Sling Retropubic System

GYNECARE TVT™ Retropubic System is a retropubic mid-urethral sling used for the treatment of female stress urinary incontinence. The needle curvature and tip radius is designed to maintain contact with the posterior aspect of the pubic bone during passage. The system had a 91% objective cure rate and a 87% subjective cure rate reported from a 17 year study.1-5 Also, the system had significantly lower rates of urinary obstruction/retention6 and has been evaluated in over 100 RCTs.7

Request Demo
Instructions for Use

 Instructions for use are found in the information that accompanied the product packaging.

View Specs
TVT Retropubic
Ethicon Logo

Supporting Documentation

Product Support

GYNECARE TVT Family of Products Brochure

Download PDF

Product Specifications

Product Code

Description

 
810041A GYNECARE TVT™ with abdominal guides 

Product Code

Description

 
810041B GYNECARE TVT™ (mechanical cut mesh) 

Product Code

Description

 
810041BL GYNECARE TVT™ (laser cut mesh) 

Product Code

Description

 
830041 GYNECARE TVT™ Undyed 

Product Code

Description

 
830041B GYNECARE TVT™ (mechanical cut mesh) 

Product Code

Description

 
830041BL GYNECARE TVT™ (laser cut mesh) 

References

1.Nilsson CG, Palva K, Aarnio R, Morcos E, Falconer C (2013) Seventeen years’ follow-up of the tension-free vaginal tape procedure for female stress urinary incontinence. Int Urogynecol J 24(8):1265– 1269.

2. Aigmueller T, Trutnovsky G, Tamussino K, et al. (2011) Ten-year follow-up after the tension-free vaginal tape procedure. Am J Obstet Gynecol 205(5):496.e1–5.

3.Olsson I, Abrahamsson AK, Kroon UB (2010) Long-term efficacy of the tension-free vaginal tape procedure for the treatment of urinary incontinence: a retrospective follow-up 11.5 years post-operatively. Int Urogynecol J 21:679–683.

4. Nilsson CG, Palva K, Rezapour M, Falconer C (2008) Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int Urogynecol J 19:1043–1047.

5. Bjelic-Radisic V, Dorfer M, Greimel E, Frudinger A, Tamussino K, Winter R (2006) Quality of life and continence 1 year after the tension-free vaginal tape operation. Am J Obstet Gynecol 195:1784-1788.

6.Magee G, Roy S, Hinoul P, Moretz C, Kozarev R, Waters H, Whitmore K. A real-world comparative assessment of complications following various mid-urethral sling procedures for the treatment of stress urinary incontinence. J Long Term Eff Med Implants. 2012. 22(4): 329–340.

7. Published Sling Data Analysis. March 2013. Ethicon, Inc.

GYNECARE TVT™ FAMILY OF PRODUCTS
ESSENTIAL PRODUCT INFORMATION
INDICATIONS/INTENDED USE

GYNECARE TVT™ Tension-free Vaginal Tape
The GYNECARE TVT Device is intended to be used as a pubo-urethral sling for treatment of Stress Urinary Incontinence (SUI), for female urinary incontinence resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The GYNECARE TVT Introducer and Rigid Catheter Guide are available separately and are intended to facilitate the placement of the GYNECARE TVT DEVICE.

The GYNECARE TVT Introducer is a reusable device intended to aid in the placement of the GYNECARE TVT Device retropubically.

The GYNECARE TVT Rigid Catheter Guide is a reusable device intended to facilitate the identification of the urethra and bladder neck during the placement of the GYNECARE TVT Device.

GYNECARE TVT™ with abdominal guides Tension-free Support for Incontinence
The GYNECARE TVT Device is intended to be used as a pubo-urethral sling for treatment of stress urinary incontinence (SUI), for female urinary incontinence resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The GYNECARE TVT Introducer, and Rigid Catheter Guide are available separately and GYNECARE TVT Abdominal Guides and Couplers are included in each kit.

The GYNECARE TVT Introducer is a reusable device intended to aid in the placement of the GYNECARE TVT Device retropubically.

The GYNECARE TVT Rigid Catheter Guide is a reusable device intended to facilitate the identification of the urethra and bladder neck during the placement of the GYNECARE TVT Device.

The GYNECARE TVT Abdominal Guides and Couplers are single use devices used to facilitate placement of the GYNECARE TVT Device when placed in a top-down retropubic fashion (also known as an abdominal approach).

GYNECARE TVT ABBREVO™ Continence System
The GYNECARE TVT ABBREVO Continence System is intended for use in women as a sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

The GYNECARE TVT ABBREVO Helical Passers and Atraumatic Winged Guide are intended to aid in the placement of the GYNECARE TVT ABBREVO Device.

GYNECARE TVT™ Obturator System Tension-free Support for Incontinence
The GYNECARE TVT Obturator Device is intended to be used in women as a sub-urethral sling for the treatment of stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

The GYNECARE TVT Obturator Helical Passers and Atraumatic Winged Guide are intended to aid in the placement of the GYNECARE TVT Obturator Device.

The GYNECARE TVT EXACT Continence System
The GYNECARE TVT EXACT Continence System is intended to be used as a pubo-urethral sling for treatment of female Stress Urinary Incontinence, resulting from urethral hypermobility and/or intrinsic sphincter deficiency.

The GYNECARE TVT EXACT Continence System Trocar is a single use device intended to aid in the placement of the GYNECARE TVT EXACT Continence System retropubically. 

The GYNECARE TVT Rigid Catheter Guide is a reusable device intended to facilitate the identification of the urethra and bladder neck during the placement of the GYNECARE TVT EXACT Continence System.

CONTRAINDICATIONS
-    As with any suspension surgery, these procedures should not be performed in pregnant patients.
-    Additionally, because the PROLENE Polypropylene Mesh will not stretch significantly, these procedures should not be performed in patients with future growth potential, including women with plans for future pregnancy.

WARNINGS & PRECAUTIONS
-    Do not use the GYNECARE TVT Family of Products in patients who are on anti-coagulation therapy.
-    Do not use the GYNECARE TVT Family of Products in patients who have a urinary tract infection.
-    Bleeding may occur post-operatively. Observe for any symptoms or signs before releasing the patient from hospital.
-    Transient leg pain lasting 24-48 hours may occur and can usually be managed with mild analgesics after a GYNECARE TVT Obturator System or GYNECARE TVT ABBREVO System procedure.
-    Since limited clinical information is available about pregnancy following pubo-urethral sling procedure with the GYNECARE TVT Family of Products, the patient should be counseled that future pregnancies may negate the effects of the surgical procedure and the patient may again become incontinent.
-    Since limited clinical information is available with delivery following a pubo-urethral procedure with the GYNECARE TVT Family of Products, in case of pregnancy, mode of delivery should be determined by the obstetrician in consultation with the surgeon.
-    Post-operatively, the patient is recommended to refrain from heavy lifting and/or exercise (e.g. cycling, jogging) for at least four to six weeks and to refrain from intercourse for at least one month.  The patients can usually return to other normal activity after one or two weeks.
-    Prophylactic antibiotics can be administered according to the surgeon’s usual practice.

PATIENT FACTORS
The GYNECARE TVT Device, GYNECARE TVT Exact, GYNECARE TVT Obturator and GYNECARE TVT Obturator are intended for use for non-pregnant adult female patients not planning future pregnancies, who are affected by stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency. Surgeons should use their surgical experience and judgment to determine if PROLENE Mesh is appropriate for certain patients.  Patient-specific factors may impair wound healing, which may increase the likelihood of adverse reactions.

ADVERSE REACTIONS / UNDESIRABLE SIDE EFFECTS
-    Punctures or lacerations or injury of vessels, nerves, structures, or organs, including the bladder, urethra, or bowel, may occur and may require surgical repair.
-    Local irritation at the wound site may occur.  
-    As with any implant, a foreign body response will occur, the extent of which may differ. This response could result in extrusion, erosion, exposure, fistula formation and/or chronic inflammation, the severity of which is unpredictable, or other adverse reactions, which may be ongoing.
-    Fistula formation, acute and chronic inflammation and ongoing risk of mesh extrusion, exposure, or erosion into the vagina or other structures or organs (such as bladder, urethra or rectum) which may be difficult to treat and result in consequent pain. Mesh extrusion, exposure, or erosion into the vagina may also cause offensive vaginal discharge.
-    Infection following transvaginal implantation. As with all surgical procedures and the implantation of foreign bodies, there is a risk of infection and PROLENE Mesh may potentiate an existing infection.
-    Pain- which may be severe and chronic.
-    Temporary or chronic voiding dysfunction (or difficulty voiding) or urinary retention/obstruction independent from that caused by overcorrection or urethral hypermobility, i.e., too much tension applied to the tape, or from misplacement of the sling or placing the sling too tightly.
-    Pain with intercourse (dyspareunia) and loss of sexual function (apareunia) which may be ongoing and may not resolve in some patients.
-    Excessive contraction or shrinkage of the tissue surrounding the mesh, and vaginal scarring from causes which include, but are not limited to, chronic inflammation and mesh exposure.
-    Neuromuscular problems, including acute and/or chronic pain in the groin, thigh, leg, pelvic and/or abdominal area, and leg weakness, may occur.
-    Recurrence of incontinence.
-    Bleeding, including hemorrhage or hematoma. 
-    One or more revision surgeries may be necessary to treat these adverse reactions. Revision surgeries may not resolve complications and are associated with a risk of adverse reactions.
-    PROLENE Mesh is a permanent implant that integrates into the tissue. In cases in which the PROLENE Mesh needs to be removed in part or whole, significant dissection may be required. Removal of the implant in whole or in part will not necessarily alleviate the patient’s symptoms. Removal of part of the implant can be difficult. Surgery to remove the whole or part of an implant can result in further scarring and tissue damage which, in turn, may have adverse outcomes including severe chronic pain which may not be able to be satisfactorily treated. Surgery to remove the whole or part of the implant may also result in recurrence of SUI. Removal of the eroded mesh will not necessarily prevent further erosions or other adverse events.

OTHER ADVERSE REACTIONS/ UNDESIRABLE SIDE EFFECTS
-    Seroma
-    Urge incontinence, including de novo urge incontinence
-    Urinary frequency
-    Urinary retention
-    Adhesion formation
-    Atypical vaginal discharge
-    Exposed mesh may cause pain or discomfort to the patient’s partner during intercourse
-    Death

The surgeon should convey adverse reactions, undesirable side effects and risks associated with the product and the procedure to the patient prior to undertaking SUI and advise the patient to contact a surgeon in case of any deviation from the normal post-operative course. Any serious incident that has occurred in relation to the device should be reported to the manufacturer and the country-competent authority.

Consult your doctor to discuss the potential benefits and risks of your treatment options and whether PROLENE mesh is appropriate for you.

For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

026356-210607

2021 Ethicon Product Catalog


© Ethicon US, LLC. 2019.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
This site is published by Ethicon US, LLC, which is solely responsible for its contents, and is intended for U.S. audiences only.
This site is intended for Healthcare Professionals. If you are a patient, it is important that you discuss information about the benefits and risks of products with your doctor.
Last updated February 20, 2019. The third-party trademarks used herein are trademarks of their respective owners. Data and usage fees may apply. See your carrier for more information.

Ethicon
         
  LinkedIn

 

Twitter

 

YouTube

 

 
Johnson and Johnson logo
Johnson & Johnson
  • Privacy Policy
  • Legal Notice
  • Do Not Sell My Personal Information
  • Contact Us
  • J&J Institute
  • Accessibility Statement
English (United States)

© Medical Device Business Services, Inc. 2021, 2022. All rights reserved.

This information is intended for use by customers, patients, and healthcare professionals in the United States only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside the United States, and the information from other sites you visit may not be appropriate for use in the United States.

You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.

Yes, Continue to External Site No, Stay Here